rs143838895
Positions:
Variant summary
Our verdict is Benign. Variant got -17 ACMG points: 0P and 17B. BP4_StrongBP6_Very_StrongBP7BS1
The NM_015340.4(LARS2):c.2307C>T(p.Ser769Ser) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00047 in 1,613,598 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.0026 ( 1 hom., cov: 30)
Exomes 𝑓: 0.00025 ( 1 hom. )
Consequence
LARS2
NM_015340.4 synonymous
NM_015340.4 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -1.71
Genes affected
LARS2 (HGNC:17095): (leucyl-tRNA synthetase 2, mitochondrial) This gene encodes a class 1 aminoacyl-tRNA synthetase, mitochondrial leucyl-tRNA synthetase. Each of the twenty aminoacyl-tRNA synthetases catalyzes the aminoacylation of a specific tRNA or tRNA isoaccepting family with the cognate amino acid. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -17 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.73).
BP6
Variant 3-45524011-C-T is Benign according to our data. Variant chr3-45524011-C-T is described in ClinVar as [Likely_benign]. Clinvar id is 226703.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr3-45524011-C-T is described in Lovd as [Likely_benign].
BP7
Synonymous conserved (PhyloP=-1.71 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00257 (391/152164) while in subpopulation AFR AF= 0.00899 (373/41506). AF 95% confidence interval is 0.00823. There are 1 homozygotes in gnomad4. There are 190 alleles in male gnomad4 subpopulation. Median coverage is 30. This position pass quality control queck.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LARS2 | NM_015340.4 | c.2307C>T | p.Ser769Ser | synonymous_variant | 20/22 | ENST00000645846.2 | NP_056155.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LARS2 | ENST00000645846.2 | c.2307C>T | p.Ser769Ser | synonymous_variant | 20/22 | NM_015340.4 | ENSP00000495093.1 |
Frequencies
GnomAD3 genomes AF: 0.00257 AC: 390AN: 152046Hom.: 1 Cov.: 30
GnomAD3 genomes
AF:
AC:
390
AN:
152046
Hom.:
Cov.:
30
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000613 AC: 154AN: 251420Hom.: 0 AF XY: 0.000442 AC XY: 60AN XY: 135884
GnomAD3 exomes
AF:
AC:
154
AN:
251420
Hom.:
AF XY:
AC XY:
60
AN XY:
135884
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000252 AC: 368AN: 1461434Hom.: 1 Cov.: 29 AF XY: 0.000198 AC XY: 144AN XY: 727072
GnomAD4 exome
AF:
AC:
368
AN:
1461434
Hom.:
Cov.:
29
AF XY:
AC XY:
144
AN XY:
727072
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00257 AC: 391AN: 152164Hom.: 1 Cov.: 30 AF XY: 0.00255 AC XY: 190AN XY: 74376
GnomAD4 genome
AF:
AC:
391
AN:
152164
Hom.:
Cov.:
30
AF XY:
AC XY:
190
AN XY:
74376
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:2
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Feb 01, 2018 | - - |
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 24, 2014 | Ser769Ser in exon 20 of LARS2: This variant is not expected to have clinical sig nificance because it does not alter an amino acid residue and is not located wit hin the splice consensus sequence. It has been identified in 1.2% (51/4406) of A frican American chromosomes from a broad population by the NHLBI Exome Sequencin g Project (http://evs.gs.washington.edu/EVS; dbSNP rs143838895). - |
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Jun 29, 2021 | - - |
LARS2-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 14, 2020 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AL_spliceai
Position offset: -14
Find out detailed SpliceAI scores and Pangolin per-transcript scores at